These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26172631)

  • 1. HelpDesk answers: do hormonal contraceptives lead to weight gain?
    Albright M; Rani S; Gavagan T
    J Fam Pract; 2015 Jun; 64(6):371-2. PubMed ID: 26172631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use.
    Berenson AB; Rahman M
    Am J Obstet Gynecol; 2009 Mar; 200(3):329.e1-8. PubMed ID: 19254592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception.
    Clark MK; Dillon JS; Sowers M; Nichols S
    Int J Obes (Lond); 2005 Oct; 29(10):1252-8. PubMed ID: 15997247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body weight and body composition of depot medroxyprogesterone acetate users.
    Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
    Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body composition and weight gain in new users of the three-monthly injectable contraceptive, depot-medroxyprogesterone acetate, after 12 months of follow-up.
    dos Santos Pde N; Modesto WO; Dal'Ava N; Bahamondes MV; Pavin EJ; Fernandes A
    Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):432-8. PubMed ID: 25047227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
    Westhoff C
    J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight and body fat changes in postpartum depot-medroxyprogesterone acetate users.
    Nyirati CM; Habash DL; Shaffer LE
    Contraception; 2013 Jul; 88(1):169-76. PubMed ID: 23177262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate.
    Modesto W; Bahamondes MV; Silva dos Santos P; Fernandes A; Dal'Ava N; Bahamondes L
    Eur J Contracept Reprod Health Care; 2014 Aug; 19(4):244-9. PubMed ID: 24923792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormones and weight change.
    Pelkman C
    J Reprod Med; 2002 Sep; 47(9 Suppl):791-4. PubMed ID: 12380408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of perceived weight gain in women using long-acting reversible contraception and depot medroxyprogesterone acetate.
    Nault AM; Peipert JF; Zhao Q; Madden T; Secura GM
    Am J Obstet Gynecol; 2013 Jan; 208(1):48.e1-8. PubMed ID: 23103344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M; Guarnaccia M; Alon J; Wiley J
    Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum adipocytokines and adipose weight gain: a pilot study in adolescent females initiating depot medroxyprogesterone acetate.
    Bonny AE; Lange HL; Hade EM; Kaufman B; Reed MD; Mesiano S
    Contraception; 2015 Oct; 92(4):298-300. PubMed ID: 26071674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance parameters in users of the injectable contraceptive depot medroxyprogesterone acetate during one year of use.
    Cursino K; Sider M; Pavin EJ; dos Santos Pde N; Bahamondes L; Zantut-Wittmann DE; Fernandes A
    Eur J Contracept Reprod Health Care; 2016; 21(1):22-9. PubMed ID: 26140543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting hormonal contraception: assessing impact on bone density, weight, and mood.
    Kaunitz AM
    Int J Fertil Womens Med; 1999; 44(2):110-7. PubMed ID: 10338269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
    Kaunitz AM
    J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive.
    Pantoja M; Medeiros T; Baccarin MC; Morais SS; Bahamondes L; Fernandes AM
    Contraception; 2010 Feb; 81(2):107-11. PubMed ID: 20103446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Depot medroxyprogesterone acetate (DMPA) injectable contraception--safe, effective but neglected method of family planning in Poland].
    Lech MM
    Wiad Lek; 2003; 56(7-8):362-8. PubMed ID: 14969166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users.
    Le YL; Rahman M; Berenson AB
    Obstet Gynecol; 2009 Aug; 114(2 Pt 1):279-284. PubMed ID: 19622988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception.
    Beksinska ME; Smit JA; Kleinschmidt I; Milford C; Farley TM
    Contraception; 2010 Jan; 81(1):30-4. PubMed ID: 20004270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.